Mobile

The trial is designed to determine the safety and efficacy of ABP 501 compared with Adalimumab in subjects with moderate to severe plaque psorasis

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-000537-12

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective for this study is to evaluate the efficacy of ABP 501 in subjects with moderate to severe plaque psoriasis, as measured by the PASI percent improvement from baseline, compared with adalimumab.

Critère d'inclusion

  • Moderate to Severe Plaque Psoriasis

Liens